Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Royalty Pharma plc

Royalty Pharma plc (RPRX) Stock Overview

Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

RPRX●NASDAQ
HealthcareMedical - Pharmaceuticals
$61.31
$0.73(1.21%)
U.S. Market opens in 38h 22m

Royalty Pharma plc (RPRX)

Meyka AI Score

Z

Key Financials

Market Cap27.2B
P/E Ratio25.51
EPS (TTM)$5.25
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 Month$57.30
3 Months$62.32
1 Year Target$61.04

RPRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Royalty Pharma plc (NASDAQ: RPRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Royalty Pharma plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RPRX on the NASDAQ shows an RSI of 63.45, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $61.04 for the NASDAQ listing.

Key metrics behind Royalty Pharma plc's NASDAQ-traded stock include a P/E ratio of 25.51 and a market capitalization of 27.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RPRX on the NASDAQ.

Price Performance (NASDAQ: RPRX)

1-Day Change
1.21%
5-Day Change
5.91%
1-Month Change
4.95%
3-Month Change
14.49%
6-Month Change
35.88%
Year-to-Date (YTD) Change
58.67%
1-Year Change
68.85%
3-Year Change
106.85%
5-Year Change
58.63%
All-Time (Max) Change
37.78%

Contact Information

https://www.royaltypharma.com
212 883 0200
110 East 59th Street, New York, NY, 10022

Company Facts

1,000 Employees
IPO DateJun 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions